Comparative Pharmacology
Head-to-head clinical analysis: BRINSUPRI versus RAMIPRIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRINSUPRI versus RAMIPRIL.
BRINSUPRI vs RAMIPRIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BRINSUPRI is a novel oral cyclin-dependent kinase (CDK) inhibitor that selectively inhibits CDK4 and CDK6, thereby blocking phosphorylation of the retinoblastoma (Rb) protein and preventing G1-to-S phase cell cycle progression. This induces cell cycle arrest in cancer cells with intact Rb function.
Ramipril is a prodrug that is hydrolyzed in the liver to its active metabolite ramiprilat, which inhibits angiotensin-converting enzyme (ACE), thereby decreasing angiotensin II production, reducing vasoconstriction, aldosterone secretion, and sodium retention.
4 mg orally once daily, with or without food.
Initial: 2.5 mg orally once daily; Maintenance: 2.5-20 mg/day in 1-2 divided doses; Maximum: 20 mg/day.
None Documented
None Documented
Clinical Note
moderateRamipril + Torasemide
"The risk or severity of adverse effects can be increased when Ramipril is combined with Torasemide."
Clinical Note
moderateRamipril + Etacrynic acid
"The risk or severity of adverse effects can be increased when Ramipril is combined with Etacrynic acid."
Clinical Note
moderateRamipril + Furosemide
"The risk or severity of adverse effects can be increased when Ramipril is combined with Furosemide."
Clinical Note
moderateRamipril + Bumetanide
Terminal elimination half-life is approximately 20-30 hours in healthy adults, allowing once-daily dosing. In renal impairment (CrCl <30 mL/min), half-life may extend to >50 hours, requiring dose adjustment.
Terminal half-life of ramiprilat is 13–17 hours (prolonged to 50 hours in renal impairment). Accumulation half-life is 110 hours after multiple doses.
Primarily renal excretion as unchanged drug (70-85%) and minor fecal elimination (10-15%). Biliary excretion accounts for <5%.
Primarily renal (60% as unchanged drug and metabolites) and fecal (40% via biliary elimination).
Category C
Category D/X
ACE Inhibitor
ACE Inhibitor
"The risk or severity of adverse effects can be increased when Ramipril is combined with Bumetanide."